急性心肌梗死溶栓治疗中应用尿激酶与瑞替普酶的效果对比

Comparison of the Effects of Urokinase and Reteplase in Thrombolytic Therapy for Acute Myocardial Infarction

目的分析急性心肌梗死溶栓治疗中应用尿激酶与瑞替普酶的效果对比。方法选取2016年11月-2017年11月本院收治80例急性心肌梗死患者,随机将患者分为两组,对照组40例使用尿激酶治疗,研究组40例使用瑞替普酶治疗,对两组患者溶栓治疗后6 h内的成功率及并发症发生情况进行比较。结果研究组患者治疗后6 h和6 h-12 h的时间段溶栓成功率分别为52.50%和27.50%,均高于对照组的37.50%和15.00%,差异无统计学意义(P>0.05);但研究组的总的时间段成功率情况为80.00%显著优于对照组的52.50%,比较差异具有统计学意义(P<0.05);研究组患者并发症发生率为7.50%,并发症发生率明显低于对照组25.00%,比较差异显著具统计意义(P<0.05)。结论临床使用瑞替普酶与尿激酶治疗急性心肌梗死患者,治疗效果佳,但和尿激酶相比,瑞替普酶治疗效果更佳,其并发症少,安全性高,值得临床推广使用。

Objective To compare the effects of urokinase and reteplase in thrombolytic therapy for acute myocardial infarction. Methods The eighty patients with acute myocardial infarction were enrolled in our hospital from November 2016 to November 2017. The patients were randomly divided into two groups, and 40 patients in the control group were treated with urokinase. The forty patients in the study group were treated with reteplase, and then the success rate and complications of the two groups were compared within 6 h after thrombolytic therapy. Results The success rate of thrombolysis in the study group at 6 h and 6 h-12 h after treatment was 52.50% and 27.50%, respectively, which was higher than that of the control group (37.50% and 15.00%). The difference was not statistically significant. However, the total time-span success rate of the study group was 80.00%, which was significantly better than that of the control group (52.50%). The difference was statistically significant (P<0.05). The complication rate of the study group was 7.50%, which was lower than that of the control group (25.00%). The difference was statistically significant (P<0.05). Conclusion The clinical use of reteplase and urokinase in the treatment of acute myocardial infarction patients, the treatment effect was significant, but compared with urokinase, the reteplase clinical treatment was more obvious, which less complications, high safety, and it was worthy of clinical promotion.